Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ANTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 2,826 | $4.22 | $11.9K Sale | Form 4 ↗ |
| Sep 9, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 585 | $6.02 | $3,522 Sale | Form 4 ↗ |
| Sep 9, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 523 | $6.02 | $3,148 Sale | Form 4 ↗ |
| Sep 8, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 5,294 | $6.02 | $31.9K Sale | Form 4 ↗ |
| Sep 8, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 4,725 | $6.02 | $28.4K Sale | Form 4 ↗ |
| Sep 3, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 3,223 | $6.07 | $19.6K Sale | Form 4 ↗ |
| Sep 3, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 2,877 | $6.07 | $17.5K Sale | Form 4 ↗ |
| Sep 1, 2026 | Sarah Joanne Williams Principal Accounting Officer | ANTX AN2 Therapeutics, Inc. | Sale | 272 | $5.53 | $1,504 Sale | Form 4 ↗ |
| Sep 1, 2026 | Margaret M. FitzPatrick Director | ANTX AN2 Therapeutics, Inc. | Buy | 2,098 | $5.53 | $11.6K Buy | Form 4 ↗ |
| Aug 17, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 18,706 | $6.01 | $112.4K Sale | Form 4 ↗ |
| Aug 17, 2026 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Sale | 16,696 | $6.01 | $100.3K Sale | Form 4 ↗ |
| Jul 8, 2026 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 5,945 | $4.17 | $24.8K Sale | Form 4 ↗ |
| May 29, 2026 | Sarah Joanne Williams Principal Accounting Officer | ANTX AN2 Therapeutics, Inc. | Sale | 265 | $4.43 | $1,174 Sale | Form 4 ↗ |
| Mar 3, 2026 | Sarah Joanne Williams Principal Accounting Officer | ANTX AN2 Therapeutics, Inc. | Sale | 327 | $1.06 | $347 Sale | Form 4 ↗ |
| Jan 6, 2026 | Lucy Day Chief Financial Officer | ANTX AN2 Therapeutics, Inc. | Sale | 5,512 | $1.01 | $5,567 Sale | Form 4 ↗ |
| Jan 6, 2026 | Stephen David Prior Chief Strategy Officer | ANTX AN2 Therapeutics, Inc. | Sale | 2,858 | $1.01 | $2,887 Sale | Form 4 ↗ |
| Jan 6, 2026 | Sanjay Chanda Chief Development Officer | ANTX AN2 Therapeutics, Inc. | Sale | 5,956 | $1.01 | $6,016 Sale | Form 4 ↗ |
| Jan 6, 2026 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 6,931 | $1.01 | $7,000 Sale | Form 4 ↗ |
| Jan 5, 2026 | Lucy Day Chief Financial Officer | ANTX AN2 Therapeutics, Inc. | Sale | 3,295 | $1.00 | $3,295 Sale | Form 4 ↗ |
| Jan 5, 2026 | Stephen David Prior Chief Strategy Officer | ANTX AN2 Therapeutics, Inc. | Sale | 3,604 | $1.00 | $3,604 Sale | Form 4 ↗ |
| Jan 5, 2026 | Sanjay Chanda Chief Development Officer | ANTX AN2 Therapeutics, Inc. | Sale | 3,295 | $1.00 | $3,295 Sale | Form 4 ↗ |
| Jan 5, 2026 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 17,923 | $1.00 | $17.9K Sale | Form 4 ↗ |
| Nov 4, 2025 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 2,819 | $1.14 | $3,214 Sale | Form 4 ↗ |
| Nov 4, 2025 | Stephen David Prior Chief Strategy Officer | ANTX AN2 Therapeutics, Inc. | Sale | 765 | $1.14 | $872 Sale | Form 4 ↗ |
| Jun 2, 2025 | Eric Easom Chief Executive Officer, Director | ANTX AN2 Therapeutics, Inc. | Buy | 10,000 | $1.07 | $10.7K Buy | Form 4 ↗ |
| May 30, 2025 | Braden Michael Leonard 10% owner | ANTX AN2 Therapeutics, Inc. | Sale | 7,000 | $1.03 | $7,210 Sale | Form 4 ↗ |
| May 30, 2025 | Braden Michael Leonard 10% owner | ANTX AN2 Therapeutics, Inc. | Sale | 425,000 | $1.01 | $429.3K Sale | Form 4 ↗ |
| May 28, 2025 | Braden Michael Leonard 10% owner | ANTX AN2 Therapeutics, Inc. | Sale | 200,000 | $1.09 | $218.0K Sale | Form 4 ↗ |
| May 28, 2025 | Braden Michael Leonard 10% owner | ANTX AN2 Therapeutics, Inc. | Sale | 100,000 | $1.16 | $116.0K Sale | Form 4 ↗ |
| May 28, 2025 | Braden Michael Leonard 10% owner | ANTX AN2 Therapeutics, Inc. | Sale | 2.00M | $1.16 | $2.3M Sale | Form 4 ↗ |
| May 28, 2025 | Margaret M. FitzPatrick Director | ANTX AN2 Therapeutics, Inc. | Buy | 8,610 | $1.18 | $10.2K Buy | Form 4 ↗ |
| Jan 3, 2025 | Lucy Day Chief Financial Officer | ANTX AN2 Therapeutics, Inc. | Sale | 2,957 | $1.34 | $3,962 Sale | Form 4 ↗ |
| Jan 3, 2025 | Sanjay Chanda Chief Development Officer | ANTX AN2 Therapeutics, Inc. | Sale | 2,957 | $1.34 | $3,962 Sale | Form 4 ↗ |
| Jan 3, 2025 | Stephen David Prior Chief Strategy Officer | ANTX AN2 Therapeutics, Inc. | Sale | 2,029 | $1.34 | $2,719 Sale | Form 4 ↗ |
| Jan 3, 2025 | Joshua M. Eizen See Remarks | ANTX AN2 Therapeutics, Inc. | Sale | 9,663 | $1.34 | $12.9K Sale | Form 4 ↗ |
| Dec 10, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 5,000 | $1.49 | $7,450 Buy | Form 4 ↗ |
| Dec 10, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 5,000 | $1.49 | $7,450 Buy | Form 4 ↗ |
| Dec 9, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 18,483 | $1.43 | $26.4K Buy | Form 4 ↗ |
| Dec 9, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 12,289 | $1.43 | $17.6K Buy | Form 4 ↗ |
| Dec 6, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 6,517 | $1.45 | $9,450 Buy | Form 4 ↗ |
| Dec 6, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 12,711 | $1.45 | $18.4K Buy | Form 4 ↗ |
| Nov 27, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 25,000 | $1.42 | $35.5K Buy | Form 4 ↗ |
| Nov 27, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 25,000 | $1.42 | $35.5K Buy | Form 4 ↗ |
| Nov 27, 2024 | Joseph S. Zakrzewski Director | ANTX AN2 Therapeutics, Inc. | Buy | 2,000 | $1.40 | $2,800 Buy | Form 4 ↗ |
| Nov 26, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 12,500 | $1.39 | $17.4K Buy | Form 4 ↗ |
| Nov 26, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 12,500 | $1.39 | $17.4K Buy | Form 4 ↗ |
| Nov 20, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 25,000 | $1.15 | $28.8K Buy | Form 4 ↗ |
| Nov 20, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 25,000 | $1.16 | $29.0K Buy | Form 4 ↗ |
| Nov 19, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 75,000 | $1.04 | $78.0K Buy | Form 4 ↗ |
| Nov 19, 2024 | Robin Shane Readnour Director | ANTX AN2 Therapeutics, Inc. | Buy | 75,000 | $1.03 | $77.3K Buy | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances